Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:

NCT ID: NCT03824964 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: February 1, 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19/CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.

NCT ID: NCT03824951 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: February 1, 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 iCAR NK cells in patients with relapsed refractory B cell lymphoma.

NCT ID: NCT03804996 Completed - B-Cell Lymphoma Clinical Trials

Study of TG-1801 in Subjects With B-Cell Lymphoma

Start date: March 5, 2019
Phase: Phase 1
Study type: Interventional

Phase 1 first in human Study to Assess the Bispecific Antibody TG-1801 in Subjects with B-Cell Lymphoma

NCT ID: NCT03804372 Recruiting - Clinical trials for Chronic Lymphoid Leukemia

The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

CLL1818
Start date: July 7, 2020
Phase: Phase 2
Study type: Interventional

In this study, we will evaluate the incidence of hepatitis B virus reactivation within the first 6 months of treatment with rituximab, standard chemotherapy and TAF in patients with diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive.

NCT ID: NCT03797261 Terminated - Clinical trials for Acute Myeloid Leukemia

A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

Start date: March 18, 2019
Phase: Phase 1
Study type: Interventional

This dose-escalation study evaluating the safety, pharmacokinetics and preliminary efficacy of venetoclax in combination with AMG 176 in participants with relapsed or refractory acute myeloid leukemia (AML) and participants with Non-Hodgkin's lymphoma (NHL)/diffuse large B-cell lymphoma (DLBCL). This study will include a dose escalation phase to identify the maximum tolerated dose/recommended phase 2 dose (MTD/RPTD) of venetoclax plus AMG 176 as well as a dose expansion phase to confirm safety, explore efficacy, and confirm the suitability of the preliminary RPTD.

NCT ID: NCT03797170 Active, not recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma

Start date: April 2, 2019
Phase:
Study type: Observational

In Europe diffuse large B-cell lymphoma (DLBCL) is a rare disease whereas in Italy it is not. Approximately 40% of DLBCL patients has refractory disease or will relapse after initial response. In onco-hematology, a role for gut microbiota (GM) in mediating immune activation in response to chemotherapy, has been suggested. In this scenario, the Investigators hypothesized that GM could play an important role in DLBCL prognosis and response to treatment, establishing a connection between lifestyle and clinical response. The project is aimed to the study of the functional GM layout in association with specific patterns of treatment response in de novo DLBCL undergoing standard first line chemo-immunotherapy. Results may build the scientific basis to design new and personalized intervention strategies (both in treatment approach and in life-style recommendations), to enhance clinical response and reduction of disease refractoriness through modulation of the gut microbial ecosystem.

NCT ID: NCT03795571 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma Recurrent

Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL

R2-GOD
Start date: January 1, 2019
Phase: Phase 1
Study type: Interventional

Previous study showed that Lenalidomide or R-GDP could achieve response in Relapse and Refractory DLBCL.The investigators therefore design this phase I study to investigate the safety and efficacy of R2-GOD in relapsed diffuse large-cell lymphoma.

NCT ID: NCT03793140 Active, not recruiting - Lymphoma Clinical Trials

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

Start date: December 31, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test any good and bad effects of the study drug, CPI-613.

NCT ID: NCT03778073 Terminated - Clinical trials for B-cell Non Hodgkin Lymphoma

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Start date: April 17, 2019
Phase: Phase 1
Study type: Interventional

Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.

NCT ID: NCT03777085 Recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)

Start date: January 10, 2019
Phase: Phase 3
Study type: Interventional

The Purpose of This Study is to Compare the Efficacy, Safety, Immunogenicity and Pharmacokinetics between TQB2303 and Rituximab in Combination With CHOP in Previously Untreated Patients with Diffuse Large B-cell Lymphoma